ABBV · Archive

ABBV · Monthly research archive

Every month we publish a fresh rating. Read prior months' commentary, ratings, and price trend at a glance.

2026-05Conserver

ABBV May 2026 · hold

AbbVie is successfully navigating the Humira patent cliff by driving strong growth in its newer immunology assets, Skyrizi and Rinvoq. The company remains a highly cash-generative powerhouse capable of supporting a robust and growing dividend.

$202.71